PDCD1 and neoplasm: Together, these observations provide a rationale for examining the therapeutic utility of PD1 inhibitors in patients with esophageal carcinomas, particularly those with high levels of detectable PD1 expression by TILs and cancer cells within biopsies of tumor tissue.